GET DAILY SIGNALSWhy Is Profusa (PFSA) Stock Down -8.77% Today?
Key Takeaways
- PFSA shares fell roughly 8.77% to $0.52 in Thursday's session, extending a multi-week slide.
- The decline pushed the stock to a fresh 52-week low, breaking below prior support with no single company-specific news catalyst driving the move.
- Secondary pressure stems from persistent fundamental concerns, including widening net losses, a substantial working-capital deficit, and substantial doubt about the company's ability to continue as a going concern.
- The selloff reflects ongoing micro- and nano-cap volatility and a weak technical posture rather than a broader market or sector-wide catalyst.
- Traders are now watching the company's upcoming third-quarter results, anticipated around November 18, 2026, for the next directional signal.
- For more detail on valuation and targets, review Profusa's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see which automated strategies are currently outperforming in this market environment.
Opening Summary
Profusa, Inc. (PFSA), a Berkeley, California-based digital health and medical-technology company developing tissue-integrated biosensors such as the Lumee Oxygen and Lumee Glucose platforms, extended its recent downturn on Thursday. The stock fell approximately 8.77% to $0.52, down from a prior-session close of $0.57, as sellers remained in control and the shares carved out a new 52-week low. The decline was not tied to a fresh company announcement, reflecting instead a continuation of the sustained selling pressure and weak technicals that have weighed on the nano-cap name in recent weeks.
A Nano-Cap Under Persistent Selling Pressure
Unlike many sharp single-day moves that follow earnings, a guidance update, or an analyst action, Thursday's decline in PFSA occurred without a headline company-specific catalyst. The stock has been in a prolonged downtrend, and the latest leg lower is consistent with the pattern of elevated volatility and thin liquidity that defines many sub-$1 and nano-cap securities. With a market capitalization measured in the low hundreds of thousands of dollars and a heavily reduced share count following multiple reverse stock splits in 2026, relatively small order flows can produce outsized percentage swings in either direction.
Technical Breakdown and Fresh 52-Week Low
The move pushed PFSA through its previous low and into new 52-week territory, a bearish technical development that can trigger additional momentum selling and stop-driven exits. The shares have been trading well below their longer-term moving averages, and momentum indicators have flashed a persistent "sell" signal for weeks. A break to new lows often removes the last line of technical support and leaves the stock searching for a new equilibrium, which can extend the downdraft absent a meaningful fundamental catalyst.
Fundamental Headwinds
Beneath the price action, PFSA continues to contend with meaningful balance-sheet challenges. The company has reported recurring net losses and negative operating cash flow, and it has disclosed substantial doubt about its ability to continue as a going concern. Its latest filings describe a working-capital deficit of roughly $27 million, limited cash reserves, and reliance on equity-line and convertible financing arrangements that carry the risk of significant dilution. These factors, combined with the company's history of reverse stock splits, have kept investor sentiment cautious and provided a persistent overhang on the shares.
Market Context and Trading Activity
The decline in PFSA was largely idiosyncratic rather than a reflection of broad healthcare or biotech weakness. The company's stock moves with a very low correlation to major indices and sector ETFs, and Thursday's slide did not correspond to any evident sector-wide or macro-driven catalyst. Trading in the name remains thin relative to the wide daily ranges, a liquidity profile that magnifies volatility and makes the stock particularly sensitive to sentiment shifts and momentum selling.
What Comes Next for PFSA
Looking ahead, the primary near-term event for PFSA is its third-quarter earnings report, anticipated around November 18, 2026. Investors will be watching for any update on the company's cash position, the status of its commercialization efforts for the Lumee Oxygen Platform in Europe, and progress on its strategic transactions in the diagnostics space. Key risks include continued operating losses, the potential for additional dilutive financing, and the uncertain path back to sustained Nasdaq compliance. Until the company can demonstrate a clearer path toward funding stability and revenue generation, the shares are likely to remain vulnerable to further volatility.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are curated into this section, giving traders a focused view of the strategies currently adapting best to evolving market dynamics. Consider exploring the page to see whether any of these automated approaches align with your own trading objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PFSA's RSI Oscillator stays in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFSA as a result. In 14 of 51 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 27%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for PFSA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.012) is normal, around the industry mean (4.142). P/E Ratio (-0.001) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. PFSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement